Atrial Fibrillation
An Introduction to Atrial Fibrillation
In recent years the management of patients with atrial fibrillation (AF) has made good progress, however it still remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity globally. Community awareness of arrhythmias and detection are important to allow early diagnosis and treatment to avoid stroke and other complications.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Professor Amir Jadidi presented results from SOLVE-AF at EHRA 2026, showing that sinus rhythm–guided substrate ablation significantly improves outcomes in persistent AF patients with atrial fibrosis and supporting a more personalized ablation strategy.
touchCARDIO Future Leaders 2026 Following the successful introduction last year of our touchCARDIO Future Leaders, we are delighted to announce that nominations are now open for the 2026 edition. This initiative celebrates the next generation of pioneers in cardiology, those whose passion, ...
Presented at EHRA 2026 by Dr David Birnie, the OCEAN trial reveals low, brief atrial fibrillation recurrence rates after successful ablation - findings that may support selective anticoagulation discontinuation while reinforcing the need for ongoing follow-up.
At EHRA 2026, new research presented by Professor Elaine Chew explores how music-based digital tools can enhance arrhythmia detection and enable personalized, AI-driven approaches to cardiovascular diagnosis and therapy.
At EHRA 2026, Pierre Jais presented results from the BEAT-PERS AF trial suggesting pulsed field ablation may offer a safer, effective alternative to radiofrequency ablation in persistent AF, prompting renewed focus on optimizing ablation strategies for this high-risk group.
Atrial fibrillation (AF) remains a major clinical challenge in Europe, with ongoing needs for greater precision, safety, and long-term durability in ablation. The recent CE Mark approval of the TactiFlex™ Duo Ablation Catheter, combining high-resolution mapping with emerging pulsed-field ablation (PFA) technology, offers a new option to help address these gaps. Dr John Silberbauer explores how the device may enhance AF treatment, reviews the supporting clinical evidence, and considers what this milestone means for physicians and patients across Europe.
The official abstracts from the Heart Rhythm Congress (HRC) 2025
Late-breaking data from ESC 2025 are set to reshape daily cardiology practice, with Dr José Luis Merino highlighting trials that challenge long-standing use of beta blockers, underscore the value of potassium optimization in ICD patients, and caution against routine aspirin in anticoagulated individuals, while also pointing to artificial intelligence as an emerging tool in clinical decision-making.
New perspectives from ESC 2025 point to cryoablation as a streamlined and safer option for managing atrial fibrillation in heart failure, offering the potential for earlier treatment and broader access in busy healthcare systems.
The POLAR-HF trial shows that early, simplified pulmonary vein isolation is safe and effective in patients with atrial fibrillation and reduced ejection fraction, reinforcing the importance of timely rhythm control without the need for complex ablation strategies.
Cardiac implantable electronic devices are undergoing rapid change, with conduction system pacing and new strategies for resynchronization therapy challenging long-standing standards. At ESC 2025, Dr Haran Burri highlights late-breaking trial data that could redefine best practice and underscores the importance of careful technique and training to translate these advances into meaningful patient benefit.
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
Today, NICE recommended pulsed field ablation (PFA) for the treatment of atrial fibrillation (AF), the most common heart rhythm disorder, affecting around 2% of UK adults.
The touchCARDIO journal Heart International has once again seen an increase in its Journal Impact Factor (JIF), rising from 1.9 in 2024 to 2.3 in 2025.
New-onset postoperative atrial fibrillation (POAF) is associated with increased risk of stroke, morbidity, mortality, respiratory failure and pneumonia, with additional treatment and thus increased postoperative cost.1–3 Clinical efforts to prevent and manage life-threatening complications after cardiac surgeries, such as POAF, ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
